Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes.
body mass index, cardiovascular diseases, c-reactive protein, diabetes complications, ischaemic heart disease, LDL-cholesterol, obesity, residual inflammatory risk, type 2 diabetes, waist-hip ratio
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
26
03
2020
revised:
25
04
2020
accepted:
04
05
2020
pubmed:
13
5
2020
medline:
25
6
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
Residual inflammatory risk (RIR) is defined as persistent circulating levels of high sensitivity C-reactive protein (hs-CRP) >2 mg/L despite an optimal (<70 mg/dL) control of LDL-cholesterol (LDL-C) and represents an emerging risk factor for the development of cardiovascular events in patients at high risk of atherosclerosis. Sparse data are available regarding the prevalence of RIR in patients with type 2 diabetes (T2D) and the clinical variables associated with hs-CRP elevation. Here, we report data from a well-characterized cohort of patients with T2D (n = 511) stratified for statins use, LDL-C goal attainment and prevalent T2D complications. Statins use and having at-target LDL-C partially affect the number of patients with inflammatory risk when compared with the whole T2D population, with an RIR prevalence of 39.2%. Among the spectra of complications, only patients with nephropathy had a higher prevalence of inflammatory risk. Total cholesterol, non-HDL-cholesterol, triglycerides, body mass index and waist-hip ratio were associated with hs-CRP, with an increased magnitude in at-target patients. Conversely, glucose-related variables were strongly associated with hs-CRP only in at-target patients, overall suggesting glycaemic control, insulin resistance, non-LDL-C lipid variables and especially central obesity as possible contributors to RIR in patients with T2D and LDL-C <70 mg/dL.
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Triglycerides
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1696-1700Subventions
Organisme : Italian Ministry of Health
ID : Ricerca Corrente to IRCCS MultiMedica
Pays : International
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720-1722.
Ridker PM. How common is residual inflammatory risk? Circ Res. 2017;120(4):617-619.
Aday AW, Ridker PM. Antiinflammatory therapy in clinical care: the CANTOS trial and beyond. Front Cardiovasc Med. 2018;5:62.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328.
Lu Y, Zhou S, Dreyer RP, Spatz ES, et al. Sex differences in inflammatory markers and health status among young adults with acute myocardial infarction: results from the VIRGO (variation in recovery: role of gender on outcomes of young acute myocardial infarction patients) study. Circ Cardiovasc Qual Outcomes. 2017;10(2):e003470.
Hwang YC, Morrow DA, Cannon CP, et al. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (examination of cardiovascular outcomes with Alogliptin versus standard of care) trial. Diabetes Obes Metab. 2018;20(3):654-659.
Kamari Y, Bitzur R, Cohen H, Shaish A, Harats D. Should all diabetic patients be treated with a statin? Diabetes Care. 2009;32((Suppl 2)):S378-S383.
Testa R, Olivieri F, Sirolla C, et al. Leukocyte telomere length is associated with complications of type 2 diabetes mellitus. Diabet Med. 2011;28(11):1388-1394.
American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S14-S31.
Prattichizzo F, Giuliani A, Mensà E, et al. Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Res Rev. 2018;48:87-98.
Kalkman DN, Aquino M, Claessen BE, et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018;39(46):4101-4108.
Kahn SE, Zinman B, Haffner SM, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006;55(8):2357-2364.
Sinha SK, Nicholas SB, Sung JH, et al. Hs-CRP is associated with incident diabetic nephropathy: findings from the Jackson heart study. Diabetes Care. 2019;42(11):2083-2089.
Prattichizzo F, La Sala L, Rydén L, et al. Glucose- lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol. 2019;26((suppl 2)):73-80.
Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515-2522.
Blaum C, Brunner FJ, Kröger F, et al. Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: implications for an anti-inflammatory treatment target population. Eur J Prev Cardiol. 2019;10. [Epub ahead of print]
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.